Kodiak Sciences to Present at the Barclays Global Healthcare Conference
A live audio webcast of the presentation will be available on the "Investor Relations" section of Kodiak's website at http://ir.kodiak.com/ and will be available for replay for a limited time following the event.
Kodiak™ is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate in clinical development for the treatment of age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in
Kodiak Contact: John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, email@example.com